Volume 25, Issue 10 (Jun 2018)
JSSU 2018, 25(10): 800-808 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Seyed Sharifi Kakhki A S, Onsory K.
Investigation of gene coding for P-120 RasGTPase activating protein in acute myeloid leukemia
. JSSU 2018; 25 (10) :800-808
URL: http://jssu.ssu.ac.ir/article-1-4178-en.html
URL: http://jssu.ssu.ac.ir/article-1-4178-en.html
Abstract: (4182 Views)
Introduction: Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and changing many genes expression are related to this disease. RAS pathway is one of the most common pathways, which may dysregulate in variety of cancers. RASA1 gene plays an important role in RAS inactivation through GTP hydrolysis. The purpose of the case-control study was to investigate the RASA1 gene expression in the patients with AML and compares it with the control group.
Methods: For this purpose, blood samples were collected from 50 patients with AML admitted to Mirza Kuchak Khan Jangali Hospital and 25 healthy people from Dr. Shariati Hospital, Tehran in 1395. RNA was extracted and after cDNA synthesis, the expression of RASA1 gene was evaluated using Real time PCR (ΔΔCT computational). Statistical analysis was performed SPSS (version 21) software and the values of P<0.05 was considered to be significant.
Results: The results indicated a decreased RASA1 gene expression among the patients compared to the control group and it statistically was significant (P= 0.0001). No significant association was observed between age (P= 0.571) and sex (P= 0.692) among the studied population. Most of the patients (66%) had WBC more than 10 (109/L) and 80% of them showed HGB more than 80 (g/dl). According to FAB subtype, most of the patients occupied M2 group and high number of AML patients had PLT and Blasts more than 50%.
Conclusion: Evaluation of RASA1 gene expression, therefore, can be used as diagnostic agents and also can have a role in prognostic of patients with AML.
Methods: For this purpose, blood samples were collected from 50 patients with AML admitted to Mirza Kuchak Khan Jangali Hospital and 25 healthy people from Dr. Shariati Hospital, Tehran in 1395. RNA was extracted and after cDNA synthesis, the expression of RASA1 gene was evaluated using Real time PCR (ΔΔCT computational). Statistical analysis was performed SPSS (version 21) software and the values of P<0.05 was considered to be significant.
Results: The results indicated a decreased RASA1 gene expression among the patients compared to the control group and it statistically was significant (P= 0.0001). No significant association was observed between age (P= 0.571) and sex (P= 0.692) among the studied population. Most of the patients (66%) had WBC more than 10 (109/L) and 80% of them showed HGB more than 80 (g/dl). According to FAB subtype, most of the patients occupied M2 group and high number of AML patients had PLT and Blasts more than 50%.
Conclusion: Evaluation of RASA1 gene expression, therefore, can be used as diagnostic agents and also can have a role in prognostic of patients with AML.
Type of Study: Original article |
Subject:
Genetics
Received: 2017/04/26 | Accepted: 2017/06/3 | Published: 2018/02/7
Received: 2017/04/26 | Accepted: 2017/06/3 | Published: 2018/02/7
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
